UNSPSC 51422367: Prednisolone succinate

This classification denotes a therapeutic glucocorticoid with the molecular formula C25H32O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7080T74ON, chemically known as (+)-prednisolone hemisuccinate, but more generally known as prednisolone succinate, which bears US NIH Compound Identifier 4897. European Medicines Agency schedules prednisolone succinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG.

Most nations, for tariff purposes, schedule prednisolone succinate under HS 29372100. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CCC(=O)O)O)CCC4=CC(=O)C=C[C@]34C)O.

UNSPSC 51422367 Prednisolone succinate is a Commodity code for a specific pharmaceutical preparation, but the recent state and local opportunities tagged under it do not reflect procurement of this steroid formulation. Instead, the posted solicitations address naloxone (an opioid antagonist) and direct-to-manufacturer pharmacy benefit arrangements—neither of which aligns with prednisolone succinate's therapeutic use or chemical classification. The code shows a significant mismatch between its nominal scope and the work actually being solicited under it in the state and local market.

Seminole County, Florida issued IFB60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems through competitive bid, with quarterly deliveries to the County Community Health Building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information from vendors about direct contracting capacity with self-insured employers and state agencies outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. Neither opportunity reflects actual demand for prednisolone succinate, and the code does not appear to see meaningful recent activity aligned to its pharmaceutical classification.